Veteran chartist Peter Brandt is flagging what he calls a “potential double top” on XRP’s weekly chart, a classic reversal setup that, if confirmed, would argueVeteran chartist Peter Brandt is flagging what he calls a “potential double top” on XRP’s weekly chart, a classic reversal setup that, if confirmed, would argue

XRP Risks Double-Top Crash Toward $0.40, Peter Brandt Warns

2025/12/18 17:30
4 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Veteran chartist Peter Brandt is flagging what he calls a “potential double top” on XRP’s weekly chart, a classic reversal setup that, if confirmed, would argue for materially lower prices — even as other traders point to a washed-out weekly RSI reading that has historically aligned with prior bottom zones.

Peter Brandt Flags XRP Double Top Pattern

Brandt posted the chart to X on Dec. 17 and didn’t bother softening the message for XRP’s online faithful. “I know in advance that all you Riplosts $XRP will forever remind me of this post — ask me if I care,” he wrote, before adding: “This is a potential double top. Sure, it may fail, and I will deal with this if it does. But for now this has bearish implications. Love it or not — you need to deal with it.”

XRP double top pattern

The chart shows XRP-USDT on Binance in weekly bars, with two highs clustered around $3.40 and $3.66 and a clearly marked support shelf near $2.00. In classical chart terms, that $2 region functions as the neckline: lose it with follow-through, and the market is no longer in “pullback inside a range” territory — it’s in “failed structure” territory.

That distinction matters because double tops tend to be less about the second peak itself and more about what happens at the midpoint low between the two peaks. Brandt’s framing reflects that: the pattern is “potential” until either support holds and price reclaims prior levels, or the neckline breaks and the market accepts lower.

In this case, Brandt’s chart is already showing XRP trading below the $2.00 line, with the most recent marker around $1.8859. That puts the focus squarely on whether the breakdown becomes a sustained weekly close-and-hold below support, or whether the move gets reversed quickly enough to treat it as a bear trap.

Or Is The XRP Bottom In?

Not everyone reading the same tape is leaning into the bearish conclusion. Trader Cryptollica posted a separate XRP/USD weekly chart (Bitstamp) on Dec. 15 highlighting the weekly RSI at roughly 33, accompanied by the comment: “$XRP WEEKLY RSI : 33 💥”. The chart highlights that, in the past five cases, similarly low readings in XRP’s weekly RSI have tended to occur around market bottoming zones.

XRP weekly RSI

Brandt was receptive to the conditional logic — specifically, the idea that a failed double top can flip from bearish to bullish if the breakdown doesn’t stick. Responding, he wrote: “Yea, if this dbl top fails then this could become exciting. I agree. I am not championing a bear case — just showing charts for what they are.”

That exchange captures the actual tension here. Momentum measures like RSI can identify stretched conditions and recurring historical zones, but they do not, on their own, invalidate a price-structure breakdown.

Notably, Brandt did not provide a price target in his comment. But the chart he shared contains enough structure to infer the standard “textbook” projection many technicians would use. With peaks near $3.60 and a neckline near $2.00, the pattern height is about $1.60. The conventional measured move subtracts that height from the neckline after a break, implying a target in the neighborhood of $0.40 if the setup fully plays out.

That is not a forecast, and it’s not a promise the market will cooperate — it’s simply the arithmetic implied by the pattern Brandt is pointing at. The more immediate question is whether XRP can reclaim the $2.00 area decisively enough to turn the breakdown into a failed move. If it can’t, the chart conversation shifts from “potential double top” to “confirmed break,” and the downside math stops being hypothetical in traders’ positioning models.

At press time, XRP traded at $1.83.

XRP price chart
Market Opportunity
XRP Logo
XRP Price(XRP)
$1.3667
$1.3667$1.3667
+0.75%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09